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For several days after antigenic stimulation, human
cytolytic T lymphocyte (CTL) clones exhibit a de-
crease in their effector activity and in their binding
to human leukocyte antigen (HLA)-peptide tetramers.
We observed that, when in this state, CTLs lose the
colocalization of the T cell receptor (TCR) and CD8.
Effector function and TCR-CD8 colocalization were
restoredwith galectin disaccharide ligands, suggest-
ing that the binding of TCR to galectin plays a role in
the distancing of TCR from CD8. These findings ap-
pear to be applicable in vivo, as TCR was observed
to be distant from CD8 on human tumor-infiltrating
lymphocytes, which were anergic. These lympho-
cytes recovered effector functions and TCR-CD8 co-
localization after ex vivo treatment with galectin di-
saccharide ligands. The separation of TCR and CD8
molecules could be one major mechanism of anergy
in tumors and other chronic stimulation conditions.
INTRODUCTION
The T cell receptor (TCR) and its coreceptor CD8, expressed on
cytolytic T lymphocytes (CTLs), cooperate in the recognition of
a complex formed by an antigenic peptide and a class I major
histocompatibility complex (MHC) molecule. The TCRab hetero-
dimer interacts with both the peptide and the surrounding groove
of the MHC class I molecule with a KD that is usually higher than
3 mM for syngeneic responses (Arcaro et al., 2001; Holler and
Kranz, 2003). In contrast, the heterodimeric coreceptor CD8ab
contacts the a3 constant region of MHC class I molecules with
a KD of 100 mM (Arcaro et al., 2001; Holler and Kranz, 2003). To-
gether, the affinity of the TCR-CD8 complexes for MHC-peptide414 Immunity 28, 414–424, March 2008 ª2008 Elsevier Inc.complexes is about 10-fold higher than that of the TCR alone
(Holler and Kranz, 2003).
CD8ab is located in lipid rafts, where it associates with the in-
tracellular tyrosine kinase p56lck (Arcaro et al., 2000, 2001).
TCRab, which is associated with the CD3g, d, 3, and z chains,
is not located in rafts, but upon binding of the CTL to the target
cell, TCR-CD3 complexes can become associated with raft-res-
ident CD8-p56lck complexes to induce signal transduction (Mon-
tixi et al., 1998; Doucey et al., 2001). Soon, additional TCR mol-
ecules concentrate into the contact region, called the
immunological synapse. This synapse matures to form a distinct
pattern, with TCR molecules located in the center being sur-
rounded by LFA-1 adhesion molecules, which are themselves
surrounded by CD45 molecules (van der Merwe et al., 2000;
Huppa and Davis, 2003). The microtubule organizing center reor-
ients itself toward the synapse and reorganizes the microtubule
network to ensure directional release of lytic granules into the
target cells (Grakoui et al., 1999; Stinchcombe et al., 2001).
Within a few hours, TCR molecules in the synapse start being
internalized, resulting in a considerable decrease of TCR mole-
cules at the cell surface. This decrease lasts only 24 hours, as
recycled and newly synthesized TCR molecules replenish the
TCR surface pool (Valitutti et al., 1995).
CTLs can be maintained in culture for several months by reg-
ular stimulation every 7 to 14 days with antigen in the presence of
growth factors, but their cytolytic activity sometimes declines or
disappears completely. We have observed that some anti-
tumoral human CD8+ CTL clones gradually lose their cytolytic
activity if, instead of being stimulated weekly with tumor cells,
they are stimulated with peptide-pulsed Epstein-Barr virus-
transformed B (EBV-B) cells, which appear to provide a stronger
stimulation. For two CTL clones, we have reported that the loss
of effector function is always associated with a loss of labeling by
human leukocyte antigen (HLA)-peptide tetramers, which are
fluorescent tetrameric complexes formed by soluble HLA mole-
cules, b2-microglobulin, and the antigenic peptide (Altman et al.,
1996; Demotte et al., 2002). The loss of tetramer binding was not
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report here that, during a substantial part of a stimulation cycle,
CTL clones have a strong reduction in their ability to bind HLA-
peptide tetramers and to secrete cytokines. We show that this
phase is linked to a dissociation between CD8 and TCR mole-
cules on the cell surface. We also show that TCR is distant
from CD8 on human tumor-infiltrating lymphocytes (TILs). This
type of anergy of TILs appears to be an extension of the de-
creased activity occurring during the normal stimulation cycle
of T lymphocytes.
RESULTS
Transient Decrease of Tetramer Binding and Effector
Functions of CTL Clones after Stimulation
Having observed that, after several cycles of stimulation, some
CTL clones lose their effector functions together with their ability
to bind HLA-peptide tetramers (Demotte et al., 2002), we set out
to examine the evolution of tetramer binding during one stimula-
tion cycle. CTL clone A10, directed against the MAGE-3 peptide
EVDPIGHLY presented by HLA-A1, was maintained by stimula-
tion every 14 days with peptide-pulsed tumor cells. Cells col-
lected 14 days after antigenic stimulation were found to have
a strong and homogeneous staining by the relevant tetramer (tet-
ramerhi phenotype). On day 0, these cells were stimulated as
usual with peptide-pulsed tumor cells in the presence of feeder
cells and IL-2. On day 4, a homogeneous decrease of tetramer
staining of more than 95% was observed (tetramerlo phenotype)
(Figure 1A). Other experiments with the same clone and with
other clones showed that CTLs were already tetramerlo by day 1
after stimulation (Figure 1D; see also Figure S1 available online).
By day 7 the CTLs had regained part of their ability to bind the
tetramer, and by day 14 they had a tetramerhi phenotype (Fig-
ure 1A). A decrease in tetramer binding was observed with tetra-
mer concentrations ranging from 1 to 100 nM (Figure S2). Sur-
face expression of the TCR is known to decrease in the hours
after stimulation, but the tetramerlo phenotype observed on
day 4 was not due to decreased surface expression of TCRa,
TCRb, CD8a, or CD8b, as the surface expression of these recep-
tor molecules was equal to that observed on day 0 (Figure 1A;
Figure S1).
We assessed the effector capability of the CTLs at various
moments of the stimulation cycle (Figures 1B and 1C). The
CTLs collected on day 0 were capable of producing IFN-g and
IL-2 upon an 18 hr stimulation with peptide-pulsed EBV-B cells.
After a 1 hr contact with the antigen, surface TCR molecules
were concentrated at the contact site between CTLs and target
cells, as expected for functional CTLs. This was also observed
for intracellular linker for activation of T cell (LAT) molecules
and for CD3z molecules (data not shown). In contrast, CTLs col-
lected on day 4 failed to release IFN-g or IL-2 upon contact with
peptide-pulsed cells and did not recruit TCRb, LAT, or CD3zmol-
ecules at the contact site. By day 14, the CTLs had recovered
their ability to release IFN-g upon antigen contact. A similar anal-
ysis was performed with ten other CTL clones (Figure S3). After
stimulation, a transient decrease in tetramer staining and in cyto-
kine production of more than 90% was observed for the clones
tested.The time course of the recovery of tetramer binding of CTL
clones was dependent on the conditions of antigenic stimulation.
Data obtained with CTL clone 5, another anti-MAGE-3.A1 CTL
clone, are shown in Figure 1D. After stimulation with peptide-
pulsed irradiated tumor cells, a strong decrease of tetramer
binding was observed, and the initial tetramer binding was
recovered within 2 weeks. In contrast, after stimulation with pep-
tide-pulsed EBV-B cells, the CTLs showed low tetramer binding
for 2 weeks and recovered the initial amount of binding only after
4 weeks (Figure 1D). After phytohemagglutinin (PHA) stimulation,
the tetramerhi phenotype was also recovered only after 4 weeks.
Moreover, repeating the stimulation with peptide-pulsed cells
during the tetramerlo phase appeared to extend this phase indef-
initely (Figure 1E). Taken together, these data support the notion
that the duration of the tetramerlo phenotype correlates with the
strength and duration of antigenic stimulation.
Transient Decrease of Tetramer Binding
of Anti-EBV T Cells Stimulated Ex Vivo
We wondered whether the reduced tetramer binding observed
after stimulation of long-term CTL clones could also be observed
with blood T cells stimulated ex vivo. We identified an individual
with a high percentage (1.7%) of CD8+ blood T cells that were
stained with an HLA-A2 tetramer bound to an EBV peptide
encoded by BMLF1. When freshly collected blood T cells were
stimulated with the BMLF1 peptide, almost no tetramerhi cells
were detected for 1 week (Table 1). On day 20, 15% of the CD8+
cells were stained with the tetramer, indicating not only a recov-
ery of the tetramerhi phenotype but also a selective proliferation
of the anti-BMLF1 cells. A similar decrease in tetramer binding,
followed by recovery, was observed upon stimulation with PHA.
Stimulation with an irrelevant peptide did not result in a tetramerlo
phase. We conclude that the transient loss of tetramer staining
observed during the stimulation cycle of functional T cell clones
is also observed in freshly collected lymphocytes.
TCR and CD8 Colocalize on Tetramerhi
but Not Tetramerlo CTLs
To understand why cells that expressed both CD8 and TCR
molecules at their surface in normal amounts failed to bind to
HLA-peptide tetramers, the surface distribution of CD8 and
TCR molecules was compared in tetramerlo and tetramerhi sub-
populations of clone A10. Cells were double labeled with TCRb
and CD8a fluorescent antibodies and analyzed by confocal
microscopy (Figure 2A; Table S1). On most cells of the tetramerhi
population, CD8 and TCR were colocalized, appearing as a con-
tinuous yellow ring on the equatorial sections. In contrast, on
most cells of the tetramerlo population, separation of TCR and
CD8 was obvious, with TCR (red) appearing as an inner ring
and CD8 (green) appearing as an outer ring. As expected for
colocalizing molecules, TCR and CD8 showed a uniform cocap-
ping on tetramerhi CTLs and did not cocap on tetramerlo cells
(Figure 2B).
The ultrastructural correlate of the two rings in the tetramerlo
state remains unclear because the antibodies used for confocal
microscopy have failed thus far to produce sufficient immuno-
gold labeling for electron microscopy. One hypothesis that
would be compatible with the distance observed between the
inner TCR ring and the outer CD8 ring is a localization of CD8Immunity 28, 414–424, March 2008 ª2008 Elsevier Inc. 415
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Correcting Anergy of Tumor-Infiltrating T CellsFigure 1. Time Course of Tetramer Binding and Effector Functions of Cytolytic T Lymphocytes
(A–C) Cytolytic T lymphocyte (CTL) clone A10 was stimulated on day 0 with peptide-pulsed tumor cells in the presence of feeder cells and IL-2.
(A) To assess tetramer binding, staining with an A1/MAGE-3 PE-labeled tetramer (5 nM) was performed at room temperature (RT). Staining with anti-TCRa, anti-
TCRb, anti-CD8a, and anti-CD8b was performed at 4C. The mean fluorescence index (MFI) is the geometric mean of the fluorescence as measured by flow
cytometry for CD3+ cells. Results shown are representative of more than 20 experiments with more than 10 CTL clones.
(B) To assess effector functions, CTLs (5,000) collected at the indicated time were cocultured overnight with HLA-A1 EBV-B cells pulsed with 1 mM peptide or not
pulsed. IFN-g and IL-2 were then measured in triplicate in the supernatant of the coculture by ELISA and cytokine bead array (CBA) analysis, respectively. Results
shown are representative of five experiments. Error bars represent standard deviation of triplicate measurements.
(C) To assess the ability to form synapses, peptide-pulsed EBV-B cells (1.5 3 105) were attached to coverslips and cocultured for 1 hr with 3 3 105 CTLs. Cells
were fixed, labeled with an anti-TCRb primary antibody and a secondary antibody coupled to Alexa 488 (green), and examined by confocal microscopy. The same
experiment was performed with CTL clone F3.2, with very similar results.
(D) CTL clone 5 was stimulated on day 0 with peptide-pulsed tumor cells, peptide-pulsed EBV-B cells, or phytohemagglutinin (PHA) and feeder cells. Tetramer
labeling was performed at RT with an A1/MAGE-3 PE-labeled tetramer (5 nM).
(E) Cells of CTL clone 5 were repeatedly stimulated on the days indicated (arrows) with peptide-pulsed tumor cells. The same experiment was performed twice
with CTL clone 5 and twice with another CTL clone, with very similar results.416 Immunity 28, 414–424, March 2008 ª2008 Elsevier Inc.
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the bottom of microvilli or in intermicrovillar membrane domains,
as previously reported (Singer et al., 2001). CTLs, which have
a cell diameter of 10 mm, are known to bear abundant microvilli
of about 0.5 mm in length (Majstoravich et al., 2004). This is
also the case for our CTLs (Figure 2C).
To examine whether TCR and CD8 molecules that appeared to
be colocalized on tetramerhi CTLs are close enough to cooperate
in binding to HLA-peptide tetramers, fluorescence resonance
energy transfer (FRET) can be used. Upon excitation at the donor
fluorochrome wavelength, transfer of energy from the donor to
the acceptor fluorochrome is evaluated by measuring the accep-
tor fluorescence emission. Transfer occurs provided that the dis-
tance between the two molecules is shorter than 10 nm. On
a structural basis, a proximity closer than 10 nm is compatible
with joint binding of a TCR and a CD8 molecule to the same
MHC-peptide complex. Tetramerlo and tetramerhi populations
were labeled with a TCRb antibody coupled to phycoerythrin
(PE) (donor) and CD8a antibody coupled to Alexa 647 (acceptor).
A substantial transfer of energy was observed only with the cells
of the tetramerhi population, indicating that the TCR and CD8
molecules were very close to each other in that population,
and not in the tetramerlo population (Figure 2D). Similar results
were obtained using a microscopy-based FRET approach,
namely donor recovery after acceptor photobleaching (Fig-
ure S5). Thus, our data suggest that TCR and CD8 are constitu-
tively associated on the surface of functional CTLs. The corecep-
tor CD8 has a critical role in TCR binding and activation, and our
data suggest that the mere separation of TCR and CD8 is suffi-
cient to explain the functional impairment of the tetramerlo
CTLs. In line with these results, we observed that, 4 days after
stimulation, the tetramer binding of a CD8-independent CTL de-
creased only slightly, but this did not result in a decreased ability
to release cytokines upon stimulation (Figure S6).
Recovery of Tetramer Binding and Effector Function
by Restoring Proximity of TCR and CD8
Because TCR and CD8 coreceptors are separated on tetramerlo
cells, we considered the possibility that some molecules anchor
them in different locations on the cell membrane. It has been
shown that p56lck anchors CD4 in lipid rafts localized on micro-
villi (Foti et al., 2002). p56lck is also known to bind to CD8 by
a zinc-dependent process (Barber et al., 1989; Lin et al., 1998).
Table 1. Loss of Tetramer Staining of Anti-EBV T Cells Analyzed
Ex Vivo
Stimulation
CD8+ Tetramerhi Cells (%)
Day 0 Day 4 Day 8 Day 20
peptide BMLF1.A2 1.7 <0.1 <0.1 15.0
irrelevant peptide 1.7 1.5 1.4 1.4
PHA 1.7 <0.1 0.2 1.5
Freshly collected blood mononuclear cells were stimulated with either the
BMLF1 peptide GLCTLVAML or the irrelevant peptide MelanA26–35 at
5 mM or with phytohemagglutinin (PHA; 0.5 mg/ml) and cultured in
medium with 10% HS and IL-2 (50 U/ml). Cells were stained for tetramer
binding, before stimulation and at days 4, 8, and 20 after stimulation, with
an A2-BMLF1 PE-labeled tetramer (5 nM) and a CD8 antibody. Data are
given as percentages of tetramerhi cells among the CD8+ cells.If p56lck acts as the anchoring molecule that keeps CD8 at a dis-
tance from TCR in tetramerlo cells, one might expect that a zinc
chelator could release CD8 and therefore restore the proximity of
CD8 to TCR. Tetramerlo cells were treated for 2 hr with the zinc
chelator o-phenanthroline, after which they partially regained tet-
ramer binding as well as FRET between TCR and CD8 (Figure 3).
These cells were then washed and incubated overnight with
antigen-presenting cells, after which they were found to have
recovered the ability to release IFN-g. (The cells were incubated
overnight in the absence of o-phenanthroline because p56lck-
CD8 interactions are essential for T cell signaling.)
Regarding the possibility of TCR anchoring at a distance from
CD8, it has been proposed that N-glycosylated TCR molecules
belong to a surface glycoprotein lattice clustered by extracellular
galectin-3 (Demetriou et al., 2001; Morgan et al., 2004). This lec-
tin binds with high affinity to N-acetyllactosamine (LacNAc) mo-
tifs located near the end of N-linked branched sugar structures
bound to asparagine residues of surface proteins. Lattice forma-
tion occurs because galectin forms homopentamers (Ahmad
et al., 2004). FRET analysis revealed a colocalization between
galectin-3 and TCR on tetramerlo CTLs, but not on tetramerhi
CTLs, whereas no proximity of galectin-3 and CD8 was observed
on either type of cell (Figure 4).
When tetramerlo CTLs collected 4 days after stimulation were
treated for 2 hr with LacNAc, a competitive binder to galectin,
TCR-CD8 colocalization as measured by FRET was largely
restored together with tetramer binding and IFN-g release (Fig-
ure 3). A similar but smaller effect was observed with lactose,
a less potent galectin ligand. Treatment of tetramerlo cells with
sucrose, which does not bind to galectin-3, had no effect. Treat-
ment with neuraminidase, which cleaves sialic acid from many
glycans, had an effect similar to lactose (data not shown). This
effect, which was observed previously with murine CTLs (Kao
et al., 2005), may be due to the presence of a sialic acid, which
may increase the affinity for galectin, next to the LacNAc motif
of galectin-binding proteins. Swainsonine is an inhibitor of
a-mannosidase II, which is involved in the N-glycosylation pathway
that produces the branched sugar structures carrying LacNAc
motifs. Swainsonine was added to the CTL medium before
antigenic restimulation. On day 4, the cells showed increased
tetramer staining, increased TCR-CD8 FRET efficiency, and an
increased ability to release IFN-g upon antigenic stimulation
compared to untreated cells (Figure 3). Treating tetramerhi cells
with any of the compounds had no effect on tetramer binding.
An increased interaction of TCR with galectin-3 upon CTL
stimulation could result from increased galectin-3 secretion after
stimulation, a higher abundance of LacNAc motifs on TCR, or
both. We observed that antigenic stimulation induced galectin-
3 secretion by CTLs (data not shown), but this did not appear suf-
ficient to explain the loss of tetramer binding by more than 80%
of CTLs, as we found that only 30% of CTLs became tetramerlo
when galectin-3 was added to the medium of tetramerhi CTLs at
a concentration about 5-fold higher than that found in the me-
dium of stimulated CTLs (Figure 5). This suggests that stimula-
tion of CTLs also results in a modification of the glycosylation
of surface glycoproteins that renders them more susceptible to
bind to galectin-3. b1,6-N-acetylglucosaminyltransferase V
(MGAT5) appears to be a key enzyme for the biosynthesis
of N-glycans with high affinity for galectin-3 (Demetriou et al.,
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Tetramerhi cells of CTL clone A10 had not been in contact with antigen for 15 days, whereas the tetramerlo cells of CTL clone A10 had been stimulated with
peptide-pulsed cells 4 days before analysis.
(A) Cells were attached to coverslips, fixed, and double stained with TCRb antibody and Alexa 568 secondary antibodies (red) and with CD8a antibody and Alexa
488 secondary antibodies (green). The profiles of red and green fluorescence intensities in equatorial sections were analyzed in both subpopulations for 40 cells
(Table S1).
(B) Cells were attached to coverslips but not fixed and directly double stained as in (A). Cells were then fixed and incubated overnight at RT.
(C) Scanning electron microscopy image of CTL clone A10.
(D) Cells were stained with anti-TCRb-PE (donor), anti-CD8a-Alexa 647 (acceptor), or both. Cells were then fixed and analyzed by flow cytometry for fluorescence
resonance energy transfer (FRET). Similar results were obtained when CTLs were fixed before being stained with antibodies. FRET efficiency was calculated
according to Doucey et al. (2003) and expressed as FRET units. Results shown are representative of five experiments. Additional controls are shown in Figure S4.2001; Morgan et al., 2004). MGAT5 has been reported to
increase after mouse T cell activation (Demetriou et al., 2001),
but we found no increase after human CTL activation (data not
shown). Identification of the glycosylation modifications of the
TCR that result in increased binding to galectin-3 will require
further experiments.
TCR and CD8 Do Not Colocalize on Tumor-Infiltrating
Lymphocytes
It has been widely reported that human solid tumors and tumor
ascites are infiltrated by T cells (Ioannides et al., 1991; Yannelli
et al., 1996; Zorn and Hercend, 1999). Detailed study of mela-
noma tumors indicates that most of these tumor-infiltrating lym-
phocytes (TILs) are directed against tumor-specific antigens
(Germeau et al., 2005; Lurquin et al., 2005). These TILs appear
to be ineffective in situ, as the tumors are clearly progressing.
It was not possible to analyze tetramer staining on TILs because418 Immunity 28, 414–424, March 2008 ª2008 Elsevier Inc.the HLA-peptide complexes recognized by the TILs have not
been characterized. We therefore resorted to FRET analysis to
examine whether TCR and CD8 failed to colocalize on these
anergic TILs. We were unable to obtain enough TILs from a mel-
anoma metastasis, but we obtained CD8+ TILs in sufficient num-
bers from a breast carcinoma lung metastasis and from carci-
noma ascites. No marked transfer of energy between TCR and
CD8 was measured on CD8+ TILs isolated from these tumors
(Figure 6A), indicating a lack of colocalization, whereas a clear
transfer of energy was measured on CD8+ blood T cells. In con-
trast, FRET was clearly positive on CD8+ T cells isolated from
a kidney allograft resected because of a chronic rejection pro-
cess. The transfer of energy was equivalent to that measured
on the control tetramerhi CTL clone, indicating that TCR and
CD8 colocalize on these T cells obtained during graft rejection
(Figure 6A). We conclude that TIL anergy is associated with
a lack of TCR colocalization with CD8.
Immunity
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Can Be Restored by LacNAc Treatment
CD8+ TILs from a gastric carcinoma ascites were analyzed for
TCR-CD8 FRET after treatment with LacNAc. After 5 hr of LacNAc
treatment, the TILs had recovered the same amount of TCR-CD8
FRET as that observed on tetramerhi CTLs (Figure 6B). We ob-
tained similar results with TILs isolated from an ovarian carcinoma
ascites (Figure 6B, patient 1). In line with the lack of TCR-CD8 co-
localization observed on freshly isolated TILs, these TILs failed to
Figure 3. Recovery of CTL Effector Function by Restoring TCR
Proximity to CD8
Cells of CTL clone A10 were collected on day 0 and 4 days after stimulation
with HLA-A1 MAGE-3+ tumor cells. Swainsonine (0.5 mM) was added on day
0, before stimulation. Cells were stained at RT with an A1/MAGE-3 PE-labeled
tetramer. White arrows indicate the MFI for tetramerhi cells collected on day 0;
black arrows indicate the MFI for tetramerlo cells collected on day 4. FRET
experiments were performed as in Figure 2. Where indicated, cells collected
on day 4 were treated for 2 hr with either o-phenanthroline (30 mM), lactose
(100 mM), N-acetyllactosamine (LacNAc; 1 mM), or sucrose (100 mM). Cells
were washed and analyzed for tetramer staining and TCR-CD8 FRET. To as-
sess effector function, 10,000 washed CTLs were cocultured with 10,000 pep-
tide-pulsed EBV-B cells. IFN-g was estimated in triplicate by ELISA in the su-
pernatant after overnight coculture. Only the averages are indicated. Standard
deviations were below 8%, except after sucrose treatment (14%). The same
experiment was performed with CTL clone 5, with very similar results.produce IFN-g during an overnight stimulation either with a mixed
population of tumor cells, B cells, and macrophages collected
from the same ascites or with allogeneic EBV-B cells (Figure 6C,
patient 1), and they showed a very low response to anti-CD3
and anti-CD28 stimulation. Overnight incubation of these TILs
with 1 mM LacNAc boosted their IFN-g response to stimulation
with these antigens by more than 10-fold (Figure 6C). The same
observation was made for the release of TNF-a, IL-4, IL-5, and
IL-10 (data not shown). Similar results were obtained with TILs
isolated from other carcinoma ascites (Figure 6C).
As mentioned above, we measured clear TCR-CD8 FRET on
kidney-infiltrating CD8+ T cells isolated from a kidney allograft
resected because of a chronic rejection process. As expected,
these T cells released IFN-g upon stimulation with allogeneic
EBV-B cells or beads coated with anti-CD3 and anti-CD28. Treat-
ment with LacNAc did not result in increased IFN-g production
(Figure 6D). Thus, treatment with LacNAc appears to be effective
only on T lymphocytes where TCR and CD8 do not colocalize.
DISCUSSION
We report here that, after antigenic stimulation, human CD8+
CTL clones enter a transient state characterized by markedly re-
duced HLA-peptide tetramer binding despite having normal
amounts of TCR and CD8 surface expression. The transient
loss of tetramer binding is accompanied by an alteration in
T cell effector function, in particular a decreased ability to release
IFN-g upon further antigenic stimulation. The time required to
recover a tetramerhi phenotype, which can be several weeks,
correlates with the strength of the antigenic stimulation. Rapid it-
eration of the stimulation maintains the CTLs in their tetramerlo
phenotype. These results raise the possibility that this phenom-
enon applies to CTL stimulation in vivo. This may explain why,
under persistent antigen exposure such as that occurring within
a tumor mass or during chronic viral infection, CTLs are in
a blocked, anergic state, which can be reversed in the absence
of antigen.
Several groups have reported that, in murine CTLs, reduced
tetramer binding is often associated with decreased effector
function. After in vitro stimulation of anti-influenza CD8+ T cells
from TCR-transgenic animals, a transient loss of tetramer bind-
ing was observed from day 1 to day 4 and was associated with
reduced TCR signaling and diminished effector activities (Drake
Figure 4. TCR and Galectin-3 Colocalize on Tetramerlo but Not
Tetramerhi CTLs
Cells of CTL clone A10 were stained at 4C with anti-TCRb-PE (donor) or anti-
galectin-3-PE (donor) and with anti-CD8b-Alexa 647 (acceptor) or anti-TCRb-
Alexa 647 (acceptor). Cells were then fixed and analyzed by flow cytometry for
FRET. Similar results were obtained with two different CTL clones.
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pressed a TCR specific for tumor antigen gp33. TILs had an ac-
tivated phenotype but lacked effector cell functions. These TILs
bound MHC tetramers only after T cell purification and a resting
period in vitro (Blohm et al., 2002). Schwartz and colleagues
transferred CD4+ T cells from TCR-transgenic mice into hosts
constitutively expressing the antigen recognized by the trans-
ferred T cells. Within 2 weeks, a massive expansion of the T cells
was observed, most of which were hyporesponsive to further
in vitro stimulation. This hyporesponsiveness disappeared grad-
ually after the cells were transferred into new hosts that did not
express the antigen (Schwartz, 2003). Several groups have re-
ported similar observations with CD8+ and CD4+ T cells (De Mat-
tia et al., 1999; Radoja et al., 2001; Kaech et al., 2002). It has
been proposed that this reversible loss of function in the pres-
ence of an overwhelming antigen level, which has been named
anergy, might protect against excessive side effects of immune
responses against viral infection (Oxenius et al., 1998). Murine
myeloid-derived suppressor cells, by generating reactive oxy-
gen species and peroxynitrite, induce nitration of tyrosines on
TCR and CD8 molecules, making T cells unable to bind soluble
peptide-MHC complexes and to respond to the specific peptide
(Nagaraj et al., 2007). This loss of function, which may be an
important mechanism of tumor escape in mice, is permanent,
contrary to the transient anergy described above in murine
models and in this report for human T cells.
One of our important findings is the loss of colocalization of
TCR and CD8 molecules on CTLs that have low effector function
and a low ability to bind tetramers. Our data also suggest a con-
stitutive association of TCR and CD8 on the surface of functional
Figure 5. Influence of Galectin-3 and TCR Stimulation on Tetramer
Binding
CTL clones 5 and F3.2 were collected 15 days after the last antigenic stimulation
and had a homogeneous tetramerhi phenotype. CTLs were stimulated with or
without beads coated with both anti-CD3 and anti-CD28 antibodies in the pres-
ence of IL-2 but without feeder cells and in medium without human serum (HS).
Galectin-3 (1 mg/ml) was added to the medium on day 0 where indicated. Stain-
ing with an A1/MAGE-3 PE-labeled tetramer (5 nM) was performed on day 4.420 Immunity 28, 414–424, March 2008 ª2008 Elsevier Inc.T cells, in agreement with several previous reports (Beyers et al.,
1992; Suzuki et al., 1992; Kwan Lim et al., 1998; Doucey et al.,
2003) but in contradiction with others (Lee and Kranz, 2003;
Yachi et al., 2005). The critical role of the coreceptor CD8 in
the binding of TCR to MHC-peptide complexes has been amply
documented (Daniels and Jameson, 2000; Arcaro et al., 2001;
Pecht and Gakamsky, 2005). The mere separation of TCR from
the coreceptor CD8 is therefore sufficient to explain the func-
tional impairment of the tetramerlo CTLs. Our observations
were extended in vivo by FRET observation of TCR-CD8 separa-
tion on freshly collected TILs, which appeared to be anergic.
We reasoned that some molecules must anchor the CD8 and
TCR molecules in different locations of the cell membrane of tet-
ramerlo cells to explain the separation of TCR from CD8. The an-
choring of the CD8 molecules in membrane rafts of microvilli is
suggested by electron microscopy data (Singer et al., 2001).
The anchoring molecule could be p56lck, which is known to
bind CD8 in a zinc-dependent manner (Barber et al., 1989; Lin
et al., 1998; Arcaro et al., 2000, 2001; Foti et al., 2002). In agree-
ment with this model, we observed that a short treatment of tet-
ramerlo cells with a zinc chelator restored the proximity of TCR
and CD8, as well as the ability to bind tetramers. However the im-
portance of p56lck-CD8 interactions for T cell signaling probably
precludes the use of a zinc chelator in vivo for restoring effector
functions of T cells.
Regarding the anchoring of TCR, murine TCR can be trapped
within a lattice formed by extracellular galectin, in particular ga-
lectin-3, which binds to surface glycoproteins carrying LacNAc
motifs near the end of tetra-antennary N-glycans (Demetriou
et al., 2001; Morgan et al., 2004; Grigorian et al., 2007). Several
of our observations indicate that galectin-3 is involved in distanc-
ing TCR from CD8. First, a close proximity of TCR and galectin-3
was measured by FRET only on tetramerlo CTLs. Second, we ob-
served that incubation of tetramerhi CTLs with galectin-3 con-
verted 30% of them into tetramerlo CTLs. Finally, galectin-3 is
known to bind with high affinity to LacNAc motifs, and we
observed that LacNAc treatment of tetramerlo T cells rapidly re-
stored TCR-CD8 colocalization, tetramer staining, and effector
function. Although these results do not exclude a contribution
of other galectins, they support a role of galectin-3.
One possible explanation of the distancing of TCR from CD8
after stimulation could be the secretion of galectin-3 by activated
CTLs. This has been observed for activated murine T cells (Joo
et al., 2001), and we observed that activation of human CTL
clones also induced galectin-3 secretion. However, because in-
cubation of a high concentration of galectin-3 converted only
30% of the tetramerhi CTLs into tetramerlo cells, galectin secre-
tion by CTLs does not appear sufficient to explain TCR-CD8 dis-
tancing on almost all CTLs after activation. This must additionally
require a modification of the glycosylation pattern of proteins, re-
sulting in an increase in their binding to galectin-3. Activation of
murine T cells is known to cause modifications of the N-glycans
on surface glycoproteins (Comelli et al., 2006). The biosynthesis
of the N-glycans responsible for binding to galectin-3 requires
the activity of an enzymatic cascade that includes MGAT5 (De-
metriou et al., 2001; Morgan et al., 2004). MGAT5 expression
has been reported to increase after mouse T cell activation,
but we found no increase after human CTL activation (data not
shown) (Demetriou et al., 2001). It has also been reported that
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Correcting Anergy of Tumor-Infiltrating T CellsFigure 6. TCR and CD8 Do Not Colocalize on TILs, but LacNAc-Treated TILs Recover TCR-CD8 Proximity and Effector Function
CD8+ T cells were isolated using a depletion strategy from a breast carcinoma metastasis, tumor ascites, blood, or a kidney allograft resected during a chronic
rejection process. Control tetramerhi anti-MAGE-3.A1 CTL clone A10 was analyzed 2 weeks after the last antigenic stimulation.
(A) FRET experiments were performed as in Figure 2.
(B) CD8+ TILs were incubated for various time periods at 37C with 1 mM LacNAc and washed, and FRET experiments were performed as in Figure 2. Control
tetramerhi CTL clone A10 was analyzed 2 weeks after the last antigenic stimulation.
(C and D) CD8+ T cells were incubated overnight with or without 1 mM LacNAc. Washed CD8+ T cells (10,000) were cocultured with 10,000 ascites tumor cells,
10,000 of a mix of five types of allogeneic EBV-B cells, or 10,000 beads coated with CD3 and CD28 antibodies. IFN-gwas measured in triplicate in the supernatant
of an overnight coculture. The tumor cell fraction corresponds to the nonrosetting fraction of cells collected from the ascites. Error bars represent standard
deviation of triplicate measurements. There is no error bar for patient 7 because the results were obtained by CBA analysis.MGAT5 has an exceptionally high KM and that an increase in the
concentration of its substrate, UDP-GlcNAc, leads to an in-
crease in surface glycoproteins associated with galectin-3 (Sasai
et al., 2002; Grigorian et al., 2007; Lau et al., 2007), but we also
failed to observe an increase in the intracellular pool of UDP-
GlcNAc after human CD8+ T cell activation (data not shown). Fur-
ther experiments will be required to identify the mechanism of
the glycosylation modifications that follow activation of human
T cells.Human cancers progress even though patients mount a sub-
stantial anti-tumoral T cell response resulting in the accumula-
tion of anti-tumoral T cells in the tumor (Boon et al., 2006). There
is evidence for local T cell anergy in the tumor location, and sev-
eral hypotheses have been proposed to explain the local immu-
nosuppression (Boon et al., 2006). Therapeutic vaccination of
cancer patients with tumor antigens is followed by tumor regres-
sions in only a small minority of patients. We believe that in these
patients, a small number of anti-vaccine T cells succeed inImmunity 28, 414–424, March 2008 ª2008 Elsevier Inc. 421
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tion of a much larger number of other anti-tumoral T cells, possi-
bly the blocked T cells present in the tumor (Germeau et al.,
2005; Lurquin et al., 2005). These anti-tumoral T cells then pro-
ceed to the destruction of tumor cells. The results reported
here confirm once again that CD8+ T cells in ascites and in a solid
tumor are anergic and demonstrate that this anergy is correlated
with an absence of TCR-CD8 colocalization. This may be due to
the persistence of the antigen, resulting in permanent stimulation
of TILs, and to the secretion of galectin-3 by tumor cells (Dumic
et al., 2006). Compared to sera from healthy donors, galectin-3
concentration is increased in sera of tumor-bearing patients,
especially metastatic patients (Iurisci et al., 2000; Vereecken
et al., 2006).
A striking observation was our ability to restore effector func-
tions of TILs after overnight treatment with LacNAc. It is possible
that, in cancer patients, delivering LacNAc into tumors or ascites
may temporarily restore effector functions of TILs and create
conditions favorable for an effective anti-tumor T cell response.
Therapeutic vaccination combined with LacNAc treatment may
therefore induce tumor regressions in a larger fraction of patients
than vaccination alone. In addition to LacNAc, other compounds
might be tested, such as other galectin-3 ligands, agents
preventing pentamerization of galectin-3, and agents inhibiting
the N-glycosylation pathway such as swainsonine (Goss et al.,
1994, 1997).
EXPERIMENTAL PROCEDURES
Cell Lines, Media, and Reagents
The EBV-B cell lines and HLA-A1+ MAGE-3+ tumor cell line were cultured in
Iscove’s modified Dulbecco’s medium (IMDM) (Life Technologies) supple-
mented with 10% fetal calf serum (FCS), 0.24 mM L-asparagine, 0.55 mM
L-arginine, 1.5 mM L-glutamine (AAG), 100 U/ml penicillin, and 100 mg/ml
streptomycin. Tumor cell line MZ2-MEL (HLA-A1+ MAGE-3+) was cultured in
Dulbecco’s modified Eagle’s medium (DMEM) (Life Technologies) supple-
mented with 10% FCS, AAG, and HEPES-glucose. Human recombinant IL-2
was purchased from Chiron Healthcare SAS, IL-7 from R&D Systems, PHA
(HA16) from Murex, and antibody-coated beads from Dynal. All peptides
were >90% pure as indicated by analytical high-pressure liquid chromatogra-
phy. LacNAc, o-phenanthroline, swainsonine, lactose, and sucrose were
purchased from Sigma-Aldrich, and galectin-3 was purchased from R&D
Systems.
CTL Clones and Stimulation Conditions
Anti-MAGE-3.A1 CTL clones ERL06-3/3E5 (clone 5), ERL04-7A/32 (clone 32),
and LB2586-7/1F3.2 (clone F3.2) were isolated from three patients vaccinated
with autologous mature dendritic cells pulsed with the MAGE-3 peptide EVD-
PIGHLY (Thurner et al., 1999; Godelaine et al., 2003). Clone LAU147-810/A10
(clone A10) was isolated from a patient vaccinated with a canarypox virus ex-
pressing MAGE-3.A1. Clone LB1965-23 (clone 23) was described in Lonchay
et al. (2004). CTLs were restimulated in 2 ml IMDM supplemented with AAG,
10% human serum (HS), and IL-2 (50 U/ml). CTLs (3 3 105) were cultured in
24-well plates with 1 3 106 irradiated allogeneic EBV-B feeder cells
(LG2-EBV) and stimulated either with PHA (0.5 mg/ml) or with EBV-B cells
(3 3 105) or irradiated tumor cells (1 3 105) previously incubated for 1 hr at
37C with 1 mg/ml of peptide and washed.
Blood Cells and TILs
Tumor samples, tumor ascites, and resected kidney allografts were collected
after approval of the research project by the ethical committee of the Faculte´
de me´decine of the Universite´ catholique de Louvain. Mononuclear cells were
isolated from ascites by Lymphoprep (Axis-Shield PoCAS). After mechanical
dissociation, tumor samples and kidneys were incubated overnight in IMDM422 Immunity 28, 414–424, March 2008 ª2008 Elsevier Inc.medium supplemented with 1% HS, AAG, 100 U/ml nystatin (Sigma-Aldrich),
streptomycin and penicillin, 30 mg/ml gentamycin (Sigma-Aldrich), and 5 mg/ml
collagenase P (Roche). Mononuclear cells were then isolated by Lymphoprep.
T cells were isolated from mononuclear cells by rosetting with sheep erythro-
cytes (bioMe´rieux) previously treated with 2-aminoethylisothiouronium
bromide (Sigma-Aldrich). CD8+ T cells were isolated by a depletion strategy
in an AutoMACS system using a CD8+ isolation kit II (Miltenyi Biotec). CD8+
and CD8 cells were cultured in IMDM 1% HS, AAG.
Antigen Recognition Assays for CTL Clones and TILs
CTL clones (2,000 or 5,000) were stimulated for 20 hr in 150 ml of IMDM 10%
HS, AAG. Stimulations were performed with 10,000 stimulator cells, beads
coated with CD3/CD28 antibodies (1:1 ratio), or PHA at 0.5 mg/ml. Cytokine
contents were measured by ELISA using Biosource Cytoset reagents or by
flow cytometry with the Cytometric Bead Array kit Th1/Th2 (BD PharMingen).
Tetramers and Flow Cytometry
HLA-A*0101 and HLA-A*0301 complexes were folded with the MAGE-3
peptide EVDPIGHLY and the MAGE-1 peptide EADPTGHSY, respectively,
as described previously (Coulie et al., 2001; Demotte et al., 2002). HLA-A*0201
complexes were folded with the BMLF1 peptide GLCTLVAML. Phycoerythrin
(PE)-labeled tetramers were produced by mixing the biotinylated complexes
with Streptavidin-PE (BD PharMingen). Concentrations of tetramers used for
labeling refer to the concentration of the monomers. Cells were incubated for
10 min at room temperature (RT) with 5 nM tetramer and washed. Where indi-
cated, cells were then incubated for 15 min at 4C with 1/30 anti-CD3.APC
(BD PharMingen), washed again, and incubated for 30 min at 4C with 1/30
anti-CD8.FITC from IQ Product (Prosan). Cells were fixed with 1% formaldehyde
(w/v in PBS) before being analyzed on a FACSCalibur system (BD PharMingen).
In Figure 1A, cells were labeled for 30 min at 4C with anti-TCRb.FITC (BMA031;
Immunotech), washed, and fixed with 1% formaldehyde.
FRET Analyses
Cells (2 3 105) were washed in Hank’s medium 1% HS and resuspended in
50 ml of medium containing antibodies. For TCR-CD8 FRET, cells were incu-
bated with 1/20 PE-labeled anti-TCRb as donor (BMA031; Immunotech) and
1/300 Alexa 647-labeled anti-CD8 as acceptor (UCHT-4; Molecular Probes).
For galectin-3-TCR FRET, cells were labeled with 1/10 PE-labeled anti-galec-
tin-3 as donor (BD PharMingen) and 1/20 APC-labeled anti-TCRb as acceptor
(BMA031; eBioscience). For galectin-3-CD8 FRET, cells were labeled with
1/10 PE-labeled anti-galectin-3 as donor and 1/300 Alexa 647-labeled anti-
CD8 as acceptor. After 30 min of incubation at 4C, cells were washed and fixed
with 2% formaldehyde. Analysis was performed on a FACSCalibur system
(BD PharMingen) without compensation. The transfer of fluorescence was
calculated as FRET units according to Doucey et al. (2003):
FRET unit= ðE3both  E3noneÞ  ð½E3Al647  E3none
3 ½E2both=E2Al647Þ  ð½E3PE  E3none3 ½E1both=E1PEÞ;
where E1 is the fluorescence detected at 580 nm upon excitation at 488 nm, E2
is the fluorescence detected at 670 nm upon excitation at 630 nm, and E3 is
the fluorescence detected at 670 nm upon excitation at 488 nm. The different
fluorescence values (E) were measured on unlabeled cells (Enone) or cells
labeled with PE (EPE), Alexa 647 (EAl647), or Alexa 647 and PE (Eboth).
Recruitment of TCR at the Synapse and Localization of TCR andCD8
EBV-B cells (1.53 105) were incubated for 1 hr at 37C with 1 mg/ml of peptide
and washed. Cells were distributed on poly-L-lysine-coated glass coverslips
for 30 min, and 3 3 105 CTLs were added for 1 hr. Cells were then labeled
with anti-TCRb (BMA031; Immunotech), washed, labeled with an Alexa 488-la-
beled goat anti-mouse IgG antibody (H+L; Molecular Probes), and analyzed
with a confocal scanning microscope as described previously (Miro et al.,
2006). Staining of TCR and CD8 at the cell surface (Figure 2A) was performed
as follows. 1 3 105 CTLs were distributed on poly-L-lysine-coated coverslips
for 30 min. Cells were fixed with a 4% formaldehyde/0.2% glutaraldehyde mix-
ture (w/v in PBS) for 20 min at RT, washed with PBS, and incubated for 10 min
with 10 mM glycine in PBS. Cells were then incubated for 1 hr with anti-TCRb
(BMA031; Immunotech) and anti-CD8 (UCHT-4; R&D Systems) diluted in 0.2%
Immunity
Correcting Anergy of Tumor-Infiltrating T CellsBSA (Sigma-Aldrich). Cells were washed by three incubations of 5 min in
PBS/BSA and then incubated for 20 min with secondary antibodies diluted
in the same buffer: Alexa 568-labeled anti-IgG2b for TCRb, and Alexa 488-
labeled anti-IgG2a for CD8a. After a final wash, coverslips were mounted on
glass slides using ProLong Gold (Invitrogen). For cocapping studies, cells
were not fixed before incubations with the antibodies. Fluorescence images
were acquired with an LSM 510 laser scanning microscope and analyzed by
AIM software (Zeiss).
SUPPLEMENTAL DATA
One table and six figures are available at http://www.immunity.com/cgi/
content/full/28/3/414/DC1/.
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